[go: up one dir, main page]

AR084500A1 - Tableta multicapa para tratar la infeccion por hiv en un humano - Google Patents

Tableta multicapa para tratar la infeccion por hiv en un humano

Info

Publication number
AR084500A1
AR084500A1 ARP110104318A ARP110104318A AR084500A1 AR 084500 A1 AR084500 A1 AR 084500A1 AR P110104318 A ARP110104318 A AR P110104318A AR P110104318 A ARP110104318 A AR P110104318A AR 084500 A1 AR084500 A1 AR 084500A1
Authority
AR
Argentina
Prior art keywords
layer
tablet
human
hiv infection
treat hiv
Prior art date
Application number
ARP110104318A
Other languages
English (en)
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR084500(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR084500A1 publication Critical patent/AR084500A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Tabletas multicapas que contienen rilpivirina clorhidrato, emtricitabina y tenofivir disoproxil fumarato. Las tabletas son útiles para el tratamiento del HIV.Reivindicación 1: Una tableta que comprende una primera capa y una segunda capa donde: a) la primera capa comprende rilpivirina HCI y está sustancialmente libre de tenofovir disoproxil fumarato; b) la segunda capa comprende tenofovir disoproxil fumarato y está sustancialmente libre de rilpivirina HCI; y c) la tableta comprende además emtricitabina. Reivindicación 18: La tableta de acuerdo con cualquiera de las reivindicaciones 1 - 16 que además comprende una tercera capa que está interpuesta y que separa la primera capa de la segunda capa. Reivindicación 19: La tableta de acuerdo con la reivindicación 18 en la cual la tercera capa comprende lactosa monohidrato y/o celulosa microcristalina.
ARP110104318A 2010-11-19 2011-11-18 Tableta multicapa para tratar la infeccion por hiv en un humano AR084500A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19

Publications (1)

Publication Number Publication Date
AR084500A1 true AR084500A1 (es) 2013-05-22

Family

ID=45094284

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP110104318A AR084500A1 (es) 2010-11-19 2011-11-18 Tableta multicapa para tratar la infeccion por hiv en un humano
ARP200103214A AR123409A2 (es) 2010-11-19 2020-11-19 Composiciones terapéuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200103214A AR123409A2 (es) 2010-11-19 2020-11-19 Composiciones terapéuticas

Country Status (36)

Country Link
US (1) US10857102B2 (es)
EP (2) EP2640362B2 (es)
JP (2) JP2014500261A (es)
KR (1) KR101923103B1 (es)
CN (2) CN106511357A (es)
AP (1) AP3816A (es)
AR (2) AR084500A1 (es)
AU (3) AU2011329642B2 (es)
BR (1) BR112013012245B1 (es)
CA (1) CA2818097C (es)
CL (1) CL2013001402A1 (es)
CO (1) CO6761300A2 (es)
CR (1) CR20130293A (es)
DK (1) DK2640362T4 (es)
EA (2) EA025852B1 (es)
EC (2) ECSP13012700A (es)
ES (1) ES2524408T5 (es)
HK (2) HK1206592A1 (es)
HR (1) HRP20140946T1 (es)
IL (1) IL226300B (es)
MA (1) MA34735B1 (es)
ME (1) ME01980B (es)
MX (1) MX347512B (es)
MY (1) MY185604A (es)
NZ (1) NZ610729A (es)
PE (3) PE20170521A1 (es)
PH (1) PH12013501002A1 (es)
PL (1) PL2640362T5 (es)
PT (1) PT2640362E (es)
RS (1) RS53691B1 (es)
SG (3) SG10201912527XA (es)
SM (1) SMT201400150B (es)
TW (1) TWI556840B (es)
UA (1) UA114075C2 (es)
WO (1) WO2012068535A1 (es)
ZA (1) ZA201304481B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246130A1 (en) 2003-01-14 2006-11-02 Dahl Terrence C Compositions and methods for combination antiviral therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
PH12013501002A1 (en) 2010-11-19 2013-09-09 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
SG2014011548A (en) 2011-08-16 2014-09-26 Gilead Sciences Inc Tenofovir alafenamide hemifumarate
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
PL3608325T3 (pl) 2012-12-21 2022-11-07 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne
WO2015014737A1 (en) * 2013-07-29 2015-02-05 Sanovel Ilac Sanayi Ve Ticaret A.S. Multilayer tablet formulations comprising tenofovir and entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
CN113546052A (zh) * 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
WO2017175855A1 (en) * 2016-04-08 2017-10-12 Shionogi & Co., Ltd. Stabilized solid dosage form
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
JP7287906B2 (ja) * 2017-06-30 2023-06-06 ヴィーブ ヘルスケア カンパニー 組み合わせ並びにその使用及びそれによる治療
ES2995458T3 (en) 2017-12-07 2025-02-10 Univ Emory N4-hydroxycytidine derivative and anti-viral uses related thereto
CA3144534A1 (en) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Methods of treating hiv in pediatric patients with rilpivirine
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺
WO2024211882A1 (en) * 2023-04-07 2024-10-10 Navinta, Llc Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ250842A (en) 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2003045327A2 (en) 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
US20060246130A1 (en) 2003-01-14 2006-11-02 Dahl Terrence C Compositions and methods for combination antiviral therapy
EA013686B1 (ru) 2004-09-02 2010-06-30 Янссен Фармацевтика Н.В. Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
CA2625776A1 (en) 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination
AU2006325404B2 (en) 2005-12-14 2012-03-01 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
PT2487161T (pt) * 2007-02-23 2016-11-10 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
US20090270352A1 (en) 2007-05-22 2009-10-29 Ultimorphix Technologies B.V. Tenofovir Disoproxil Hemi-Fumaric Acid Co-Crystal
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
JP5611242B2 (ja) 2009-02-06 2014-10-22 ギリアード サイエンシーズ， インコーポレイテッド 併用治療のための錠剤
ES2614651T3 (es) 2009-09-21 2017-06-01 Gilead Sciences, Inc. Análogos de carbanucleósido 2' -fluorosustituidos para tratamiento antiviral
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
PH12013501002A1 (en) 2010-11-19 2013-09-09 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate

Also Published As

Publication number Publication date
AP2013006931A0 (en) 2013-06-30
CA2818097C (en) 2019-07-30
EP2640362A1 (en) 2013-09-25
DK2640362T3 (en) 2014-12-01
EA201390651A1 (ru) 2013-11-29
AR123409A2 (es) 2022-11-30
EP2640362B2 (en) 2021-12-01
JP2015131853A (ja) 2015-07-23
US10857102B2 (en) 2020-12-08
SG10201509521WA (en) 2015-12-30
EP2640362B1 (en) 2014-09-10
CL2013001402A1 (es) 2013-12-27
HK1206592A1 (en) 2016-01-15
HK1190064A1 (en) 2014-06-27
PL2640362T3 (pl) 2015-03-31
EA025852B1 (ru) 2017-02-28
PE20211657A1 (es) 2021-08-24
CN103491948B (zh) 2016-11-02
EP2826466A1 (en) 2015-01-21
IL226300B (en) 2019-05-30
SMT201400150B (it) 2015-01-15
NZ610729A (en) 2015-10-30
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
AU2018202635A1 (en) 2018-05-10
MA34735B1 (fr) 2013-12-03
PL2640362T5 (pl) 2022-05-02
PT2640362E (pt) 2014-11-28
ECSP13012700A (es) 2013-08-30
JP2014500261A (ja) 2014-01-09
EA201691695A1 (ru) 2017-11-30
HRP20140946T1 (hr) 2015-02-13
US20130243857A1 (en) 2013-09-19
MX347512B (es) 2017-04-28
AU2016208417B2 (en) 2018-04-05
UA114075C2 (xx) 2017-04-25
ZA201304481B (en) 2022-03-30
CA2818097A1 (en) 2012-05-24
BR112013012245B1 (pt) 2022-09-27
TWI556840B (zh) 2016-11-11
ES2524408T5 (es) 2022-04-25
JP6138851B2 (ja) 2017-05-31
ECSP19078196A (es) 2019-11-30
BR112013012245A2 (pt) 2016-08-09
AU2016208417A1 (en) 2016-08-18
PE20140163A1 (es) 2014-02-08
PE20170521A1 (es) 2017-05-27
MY185604A (en) 2021-05-25
KR101923103B1 (ko) 2018-11-28
MX2013005669A (es) 2013-11-04
AP3816A (en) 2016-09-30
ME01980B (me) 2015-05-20
CR20130293A (es) 2013-10-03
SG190333A1 (en) 2013-06-28
CO6761300A2 (es) 2013-09-30
TW201238612A (en) 2012-10-01
PH12013501002A1 (en) 2013-09-09
CN103491948A (zh) 2014-01-01
AU2011329642A1 (en) 2013-05-02
KR20140037799A (ko) 2014-03-27
ES2524408T3 (es) 2014-12-09
WO2012068535A1 (en) 2012-05-24
RS53691B1 (en) 2015-04-30
SG10201912527XA (en) 2020-02-27
DK2640362T4 (da) 2022-03-07

Similar Documents

Publication Publication Date Title
AR123409A2 (es) Composiciones terapéuticas
DOP2021000147A (es) Combinacion terapeutica que comprende lamivudina
USD763454S1 (en) Toe separator
CR20190073A (es) FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265)
PH12013501994A1 (en) Controlled release pharmaceutical dosage forms
EA201291158A1 (ru) Комбинированные вакцины с синтетическими наноносителями
MX2021002321A (es) Nuevos metodos.
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
PE20110119A1 (es) Asociacion entre ferroquina y artesunato para el tratamiento del paludismo
NZ738524A (en) Pharmaceutical formulations comprising rilpivirine hydrochloride, tenofovir alafenamide hemifumarate, and emtricitabine
MX2016002560A (es) Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
IN2013CH05288A (es)
PE20151282A1 (es) Combinacion de medicamentos que comprenden fenilefrina y paracetamol
CY1119845T1 (el) Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος
AR129894A2 (es) Formas de dosificación de liberación prolongada para un inhibidor de jak 1
AR125919A2 (es) Formas de dosificación de ruxolitinib de liberación sostenida
MX2011005899A (es) Composicion farmacéutica con antihistamínico no sedante y combinaciones.
TH171908A (th) องค์ประกอบบำบัดที่ประกอบรวมด้วย ริลพิวิรีน HCL (rilpivirine HCL) และ เทโนโฟเวียร์ ไดโซพรอกซิล ฟิวมาเรต (tenofovir disoproxil fumarate)
AR106645A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
MX355000B (es) Composición farmacéutica en microesferas con antihistamínico no sedante y antiemético.
ECSP15025357A (es) Formas de dosificación de ruxolitinib de liberación sostenida
MX2010006317A (es) Composicion farmaceutica oral con antihistaminico y descongestionante.
AR100910A1 (es) Forma de dosificación oral de liberación sostenida que contiene morfina y naloxona
AR098884A1 (es) Alteraciones de activación de notch en el cáncer de mama
RU2009124997A (ru) Способ лечения туберкулезного хориоретинита

Legal Events

Date Code Title Description
FC Refusal